Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An announcement from Qiagen ( (QGEN) ) is now available.
Qiagen N.V. announced a notification from the Netherlands Authority For the Financial Markets (AFM) regarding a voting rights disclosure involving BlackRock, Inc. This notification, dated June 16, 2025, details BlackRock’s indirect holdings and voting rights in Qiagen, highlighting a capital interest of 9.77% and voting rights of 10.85%. The announcement underscores BlackRock’s significant influence within Qiagen, which could impact corporate governance and decision-making processes, reflecting the strategic interests of major stakeholders.
The most recent analyst rating on (QGEN) stock is a Hold with a $42.50 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.
More about Qiagen
Qiagen N.V. operates in the biotechnology industry, focusing on providing sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research. The company is known for its products that enable the isolation and analysis of DNA, RNA, and proteins, serving a global market with a significant presence in the life sciences sector.
Average Trading Volume: 1,449,566
Technical Sentiment Signal: Strong Buy
Current Market Cap: $10.13B
See more insights into QGEN stock on TipRanks’ Stock Analysis page.